6CM
FLGT icon

683 Capital Management’s Fulgent Genetics FLGT Stock Holding History

683 Capital Management’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-15,460
Closed -$199K – 157
2019
Q4 		$199K Buy
+15,460
New +$184K 0.02% 104

Other funds holding FLGT

CFW
CA Family Wealth Beverly Hills, California $94.9M AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OWIM
Old West Investment Management Los Angeles, California $923M AUM 112.31% 1-Year Est. Return
RJT
Raymond James Trust St. Petersburg, Florida $4.6B AUM 33.54% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
HIM
Hillsdale Investment Management Toronto, Ontario, Canada $3.68B AUM 62.12% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

683 Capital Management's FLGT Position: Q1 2020 in Review

683 Capital Management sold out of Fulgent Genetics (FLGT) in Q1 2020, closing a stake of 15,460 shares — an estimated $199K sold.

683 Capital Management first reported a position in FLGT in Q4 2019 and held it in 1 quarter. The position peaked at $199K in Q4 2019. 75 funds tracked by Wall St. Rank hold FLGT as of Q1 2020.

  • 683 Capital Management reported no remaining Fulgent Genetics position as of Q1 2020 after selling out during the quarter.
  • 683 Capital Management sold 15,460 Fulgent Genetics shares in Q1 2020, an estimated $199K.
  • 683 Capital Management first reported a position in Fulgent Genetics in Q4 2019 and held it in 1 quarter.
  • 683 Capital Management's Fulgent Genetics position peaked at $199K in Q4 2019.
  • 75 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2020.

Based on 683 Capital Management's 13F filing for Q1 2020, filed 15 May 2020.